Recro Pharma, Inc.
- Jurisdiction
United States - LEI
2549004EL1Z016VYWA54 - ISIN
US75629F1093 (REPH )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€80.72M - Gross margin
20.1% - EBIT
-€1.50M - EBIT margin
-1.9% - Net income
-€11.32M - Net margin
-14.0%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: November 9, 2023 (Q3 2023)